Stockscreener 앱 받기
55.09
0.09%
-0.05
시장 영업 전:
58.85
3.76
+6.83%
Crispr Therapeutics Ag 주식(CRSP)의 최신 뉴스
Is CRISPR Therapeutics AG a good long term investmentBreakthrough profits - Jammu Links News
Director Makes Multi-Million Dollar Investment in Crispr Therapeutics AG! - TipRanks
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
CRISPR Therapeutics (CRSP) Moves 9.6% Higher: Will This Strength Last? - MSN
Leavell Investment Management Inc. Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
William Blair Issues Positive Outlook for CRSP Earnings - MarketBeat
Is It Worth Investing in CRISPR Therapeutics (CRSP) Based on Wall Street's Bullish Views? - MSN
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors - Yahoo Finance
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 5.7%Here's What Happened - MarketBeat
B & T Capital Management DBA Alpha Capital Management Buys New Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
(CRSP) Trading Report - news.stocktradersdaily.com
Crispr Therapeutics' Bright Future Is Coming Into Focus (Rating Upgrade) - Seeking Alpha
Crispr Therapeutics AG Stock Soars Amid Strategic Moves - TipRanks
CRISPR Therapeutics (CRSP) Jumps 9.6% on Biotech Rally - MSN
CRISPR Therapeutics Target of Unusually Large Options Trading (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
Genome Engineering Market Booming as CRISPR and Gene Editing - openPR.com
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 7%Should You Buy? - MarketBeat
CRISPR Stock Surges in Recent Weeks: What's Going On?CRISPR Therapeutics (NASDAQ:CRSP) - Benzinga
10 Stocks Going Wild - Insider Monkey
CRISPR’s Medical Breakthrough: Stock Surge or Mirage? - StocksToTrade
CRISPR Therapeutics (NasdaqGM:CRSP) Advances Cardiovascular Programs With Promising Trial Results - Yahoo Finance
CRISPR Therapeutics Rises Amid Positive Cardiovascular Trials - timothysykes.com
CRISPR Therapeutics’ Bold Leap: A Revolution in Cardiovascular Treatment? - StocksToTrade
CRISPR Therapeutics Reports Landmark Advances in Cardiovascular Trials - timothysykes.com
Crispr Therapeutics AG: Strategic Positioning and Growth Potential in Gene Editing - TipRanks
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market - MSN
CRISPR Therapeutics AG (NASDAQ:CRSP) Stake Boosted by Cambridge Investment Research Advisors Inc. - MarketBeat
CRISPR Therapeutics’ SWOT analysis: gene-editing pioneer’s stock faces pivotal year - Investing.com
Crispr Therapeutics AG Stock Soars Amid Clinical Advances - TipRanks
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 7.1%Here's Why - MarketBeat
Wealth Enhancement Advisory Services LLC Boosts Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG(NasdaqGM: CRSP) added to Russell 2000 Dynamic Index - MarketScreener
Crispr Therapeutics’ Stock Surges on Promising Study Update - TipRanks
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - MSN
CRISPR Therapeutics Named to TIME’s Most Influential Companies List of 2025 - GlobeNewswire
Brookline Capital Markets Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail
Goldman Sachs Reaffirms Their Hold Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail
Crispr Therapeutics downgraded to Hold from Buy at Clear Street - TipRanks
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing - MSN
CRISPR Therapeutics Reports Positive Additional Phase 1 - GlobeNewswire
CRISPR Therapeutics (CRSP) Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3 - StreetInsider
CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline - GlobeNewswire
CRISPR Breakthrough: New Drug Slashes Heart Disease Risk with 86% Cholesterol Reduction in Clinical Trial - Stock Titan
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? - Yahoo Finance
CRISPR Therapeutics AG (CRSP): A Bull Case Theory - Yahoo Finance
Crispr Therapeutics: Face The Harsh Reality Instead Of Waiting (Rating Downgrade) - Seeking Alpha
CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap UpWhat's Next? - MarketBeat
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Traders Buy High Volume of Call Options on CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat
From Now to 2032: Unpacking the Genome Editing Market's - openPR.com
CRISPR Therapeutics’ SWOT analysis: gene editing pioneer’s stock faces pivotal year - Investing.com
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - Yahoo
0.64%
0.37%
자본화:
|
볼륨(24시간):